CTLA4 and cervical carcinoma: Investigations into the probable use of immunotherapy as a viable treatment option in combating this resistance through the use of ICIs, CTLA-4 and PD-1/PD-L1, were sought out as an adjuvant to the typical concurrent chemotherapy standard of care for patients suffering from advanced-stage cervical cancer.